Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4722021 | 0.98 | L3MBTL1 (0.34) | SIGMAR1L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL4722516 | 0.95 | L3MBTL1 (0.34) | SIGMAR1L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL4723247 | 0.93 | L3MBTL1 (0.36) | SIGMAR1L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL8607396 | 0.91 | SIGMAR1 (0.33) | SIGMAR1L3MBTL1 | |
| SCHEMBL4720133 | 0.91 | HRH3 (0.31) | — | |
| SCHEMBL10444399 | 0.88 | DNM1 (0.39) | SIGMAR1L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL1206197 | 0.88 | HRH3 (0.33) | L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL28915967 | 0.86 | DNM1 (0.42) | SIGMAR1L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL4765150 | 0.86 | L3MBTL1 (0.32) | SIGMAR1L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL8894973 | 0.86 | DNM1 (0.42) | SIGMAR1L3MBTL1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1874780-A1 | 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006100591-A1 | 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | SIGMAR1 1026/4885L3MBTL1 3954/4885MEN1 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.